Asthma Treatment With Add-On Dupilumab Plus Medium-Dose Inhaled Corticosteroid (ICS) Improved Lung Function and Asthma Control Compared With Placebo Plus High-Dose ICS

被引：0
|
作者：
Busse, William [1 ]
Castro, Mario [2 ]
Lugogo, Njira [3 ]
O'Byrne, Paul [4 ]
Bacharier, Leonard [5 ]
Xia, Changming [6 ]
Hardin, Megan [7 ]
Soliman, Mena [6 ]
Sacks, Harry [6 ]
Jacob-Nara, Juby [8 ]
Rowe, Paul [8 ]
Deniz, Yamo [6 ]
机构：
[1] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[2] Univ Kansas, Sch Med, Kansas City, KS USA
[3] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[4] McMaster Univ, Hamilton, ON, Canada
[5] Vanderbilt Univ, Monroe Carell Jr Childrens Hosp, Med Ctr, Nashville, TN USA
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Sanofi, Cambridge, MA USA
[8] Sanofi, Bridgewater, NJ USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L23
引用
收藏
页码：AB368 / AB368
页数：1
相关论文
共 50 条
  • [1] Dupilumab Add-on to Medium-dose Inhaled Corticosteroid (ICS) Increases Odds of Asthma Control and Reduces FeNO Compared With Placebo Add-on to High-dose ICS
    Busse, W.
    Castro, M.
    Lugogo, N. L.
    O'Byrne, P. M.
    Bacharier, L. B.
    Xia, C.
    Hardin, M.
    Soliman, M.
    Sacks, H.
    Jacob-Nara, J. A.
    Rowe, P. J.
    Deniz, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [2] DUPILUMAB PLUS MEDIUM-DOSE INHALED CORTICOSTEROID IMPROVES OUTCOMES COMPARED WITH PLACEBO PLUS HIGH-DOSE INHALED CORTICOSTEROID IN PEDIATRIC PATIENTS WITH UNCONTROLLED ASTHMA
    Bacharier, Leonard B.
    Maspero, Jorge F.
    Papadopoulos, Nikolaos
    Guilbert, Theresa
    Xia, Changming
    Soliman, Mena
    Ledanois, Olivier
    Rowe, Paul J.
    Deniz, Yamo
    Jacob-Nara, Juby A.
    Sacks, Harry
    CHEST, 2024, 166 (04) : 4806A - 4808A
  • [3] Predictors of treatment response to high-dose ICS/LABA or medium-dose ICS/LABA plus LAMA in asthma patients - TAILOR study
    Verhamme, K. M.
    De Ridder, M.
    Rijnbeek, P.
    Mosseveld, M.
    Pedersen, L.
    Marconi, E.
    Lapi, F.
    Tan, C.
    Delmestri, A.
    Prieto-Alhambra, D.
    Nudo, E.
    Brusselle, G.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [4] Improvements in Lung Function With Tiotropium as Add-On Controller Therapy to ICS plus LABA for Patients With Symptomatic Severe Asthma
    Doherty, Dennis E.
    Tashkin, Donald P.
    Harrison, Tim W.
    Engel, Michael
    Schmidt, Hendrik
    Moroni-Zentgraf, Petra
    Kerstjens, Huib A. M.
    CHEST, 2013, 144 (04)
  • [5] Dupilumab efficacy in children with uncontrolled type 2 asthma with baseline high/medium ICS dose
    Maspero, J. F.
    Antila, M. A.
    Jain, N.
    Deschildre, A.
    Bacharier, L. B.
    Altincatal, A.
    Laws, E.
    Akinlade, B.
    Siddiqui, S.
    Jacob-Nara, J. A.
    Deniz, Y.
    Rowe, P. J.
    Lederer, D. J.
    Hardin, M.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [6] Dupilumab Efficacy in Asthma Patients With FEV1 60-80% Predicted on Medium-Dose ICS: liberty asthma quest Study
    Papi, Alberto
    Pavord, Ian D.
    Fitzgerald, J. Mark
    Corren, Jonathan
    Bardin, Philip
    Park, Hae Sim
    Rice, Megan S.
    Deniz, Yamo
    Rowe, Paul
    Staudinger, Heribert
    Amin, Nikhil
    Ruddy, Marcella
    Graham, Neil M. H.
    Teper, Ariel
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [7] Tiotropium Respimat® 2.5 mg Add-on to ICS or ICS plus controller medications Improves Lung Function in Adults and Adolescents With Mild, Moderate, or Severe Symptomatic Asthma
    Berger, William E.
    Meltzer, Eli O.
    Unseld, Anna
    Shaikh, Asif
    Engel, Michael
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB96 - AB96
  • [8] Tiotropium added to low- to medium-dose inhaled corticosteroids (ICS) versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma: A systematic review and meta-analysis
    Wang, Liqun
    Zhou, Ruirui
    Xie, Xiaohui
    JOURNAL OF ASTHMA, 2019, 56 (01) : 69 - 78
  • [9] Once-daily tiotropium Respimat® as add-on to at least medium- to high-dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status
    Dahl, R.
    Bateman, E. D.
    Casale, T.
    Pizzichini, E.
    Vandewalker, M.
    Virchow, J. C.
    Engel, M.
    Sigmund, R.
    Moroni-Zentgraf, P.
    Kerstjens, H. A. M.
    ALLERGY, 2014, 69 : 515 - 515
  • [10] Efficacy and Safety of High ICS Dose Fixed-Combination ICS/LABA/LAMA pMDI Compared with ICS/LABA and ICS/LABA plus LAMA in Patients with Uncontrolled Asthma: The TRIGGER Study
    Canonica, G. W.
    Virchow, J.
    Kots, M.
    Zuccaro, F.
    Carzana, E.
    Vele, A.
    Georges, G.
    Petruzzelli, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345